ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.83
0.43%
US Tech 100
17,173.20
1.85%
S&P 500
5,064.20
0.91%
US Dollar vs CAD
1.36629
-0.03%
Bitcoin
59,864.19
1.26%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Circio Holding Asa (0RIS)

  7. Circio Holding Asa (0RIS) News

0RIS

Circio Holding Asa (0RIS)

Circio Holding Asa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RIS
DateTimeSourceHeadlineSymbolCompany
02/28/202212:28AMPR Newswire (US)Targovax ASA strengthens management with Lubor Gaal as Chief Financial OfficerLSE:0RISCircio Holding Asa
02/28/202212:27AMPR Newswire (US)Targovax ASA strengthens management with Lubor Gaal as Chief Financial OfficerLSE:0RISCircio Holding Asa
01/12/20225:11AMPR Newswire (US)Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation NorwayLSE:0RISCircio Holding Asa
01/12/20225:09AMPR Newswire (US)Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation NorwayLSE:0RISCircio Holding Asa
12/20/20211:17AMPR Newswire (US)Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesotheliomaLSE:0RISCircio Holding Asa
12/20/20211:14AMPR Newswire (US)Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesotheliomaLSE:0RISCircio Holding Asa
11/04/20211:35AMPR Newswire (US)Targovax ASA: Third quarter 2021 resultsLSE:0RISCircio Holding Asa
11/04/20211:28AMPR Newswire (US)Targovax ASA: Third quarter 2021 resultsLSE:0RISCircio Holding Asa
10/25/20216:48AMPR Newswire (US)Targovax: Presentation material for today's webcastLSE:0RISCircio Holding Asa
10/25/20216:47AMPR Newswire (US)Targovax: Presentation material for today's webcastLSE:0RISCircio Holding Asa
10/20/20211:50AMPR Newswire (US)Targovax ASA appoints Dr. Erik Digman Wiklund as new CEOLSE:0RISCircio Holding Asa
10/20/20211:48AMPR Newswire (US)Targovax ASA appoints Dr. Erik Digman Wiklund as new CEOLSE:0RISCircio Holding Asa
10/19/20217:27AMPR Newswire (US)Targovax to present at upcoming conferencesLSE:0RISCircio Holding Asa
10/19/20217:24AMPR Newswire (US)Targovax to present at upcoming conferencesLSE:0RISCircio Holding Asa
10/06/20218:00AMPR Newswire (US)Targovax ASA: Two abstracts accepted at the SITC CongressLSE:0RISCircio Holding Asa
10/06/20217:51AMPR Newswire (US)Targovax ASA: Two abstracts accepted at the SITC CongressLSE:0RISCircio Holding Asa
09/30/202112:49AMPR Newswire (US)Targovax ASA appoints Ola Melin as Head of ManufacturingLSE:0RISCircio Holding Asa
09/30/202112:42AMPR Newswire (US)Targovax ASA appoints Ola Melin as Head of ManufacturingLSE:0RISCircio Holding Asa
09/24/20214:19AMPR Newswire (US)Targovax granted European Patent for ONCOS-102 in combination with chemotherapyLSE:0RISCircio Holding Asa
09/24/20214:17AMPR Newswire (US)Targovax granted European Patent for ONCOS-102 in combination with chemotherapyLSE:0RISCircio Holding Asa
09/16/202112:42AMPR Newswire (US)Targovax ASA: Poster at European Society for Medical Oncology (ESMO)LSE:0RISCircio Holding Asa
09/16/202112:41AMPR Newswire (US)Targovax ASA: Poster at European Society for Medical Oncology (ESMO)LSE:0RISCircio Holding Asa
08/27/20212:17AMPR Newswire (US)Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO CongressLSE:0RISCircio Holding Asa
08/27/20212:15AMPR Newswire (US)Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO CongressLSE:0RISCircio Holding Asa
08/18/202112:57AMPR Newswire (US)Targovax ASA: second quarter and first half year 2021 resultsLSE:0RISCircio Holding Asa
08/18/202112:55AMPR Newswire (US)Targovax ASA: second quarter and first half year 2021 resultsLSE:0RISCircio Holding Asa
08/16/202112:48AMPR Newswire (US)Targovax to present at upcoming scientific conferencesLSE:0RISCircio Holding Asa
08/09/202112:14AMPR Newswire (US)Targovax ASA: Invitation to presentation of Targovax's second quarter and first half 2021 results, Wednesday 18 AugustLSE:0RISCircio Holding Asa
08/09/202112:13AMPR Newswire (US)Targovax ASA: Invitation to presentation of Targovax's second quarter and first half 2021 results, Wednesday 18 AugustLSE:0RISCircio Holding Asa
07/01/20214:11AMPR Newswire (US)Targovax ASA appoints Dr Lone Ottesen as Chief Development OfficerLSE:0RISCircio Holding Asa
 Showing the most relevant articles for your search:LSE:0RIS

Your Recent History

NASDAQ
JAGX
Jaguar Health
USOTC
VPLM
Voip Pal Com (QB)
USOTC
BEGI
BlackStar Enterprise (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
BMXI
Brookmount Explorations (PK)
NASDAQ
DJT
Trump Media and Technology
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
ACRL
Atacama Resources (PK)
USOTC
CBDD
CBD of Denver (PK)
USOTC
ILST
International Star (PK)
NASDAQ
AMRN
Amarin
USOTC
BLLB
Bell Buckle (PK)
NASDAQ
MULN
Mullen Automotive
USOTC
TSOI
Therapeutic Solutions (PK)
NASDAQ
FCEL
FuelCell Energy
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved